BioNTech Results Presentation Deck

Positioned for transformative 2021 ● ● ● ● ● 24 Focused on executing ongoing BNT 162 Phase 3 trial and regulatory submission processes globally Commercial preparation activities for manufacturing and global distribution progressing for BNT162 with partners Pfizer and Fosun Advancing oncology pipeline towards multiple late-stage clinical trial initiations Additional first-in-human trials of novel product candidates expected across proprietary platforms Well capitalized to deliver on key commercial, operational and pipeline milestones Transformational opportunity ahead to positively impact the world - and accelerate our long-term vision to build a next generation immunotherapy leader BIONTECH

View entire presentation